Markedsdata leveret af TwelveData og Morningstar
Crossject SA is a France-based specialty pharmaceutical company that develops needle-free drug delivery systems for emergency medical use. Its core platform, ZENEO, is a prefilled, single-use auto-injector designed to help patients and untrained caregivers administer medication quickly and simply. The company focuses on drug-device combinations for critical conditions, including epileptic seizures, allergic reactions, adrenal crises, opioid overdose, and severe asthma. Crossject SA works across medical specialties where fast and reliable self-administration is important, supporting the broader shift toward more accessible emergency treatments. Headquartered in Dijon, France, Crossject SA combines device engineering, pharmaceutical development, and regulatory expertise to bring its products to healthcare markets.
Baseret på 2 analytikere